HRGNOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Harvard Apparatus Regenerative Technology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.21−0.02 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $38.92M
- P/E (TTM)
- –
- Dividend yield
- –
Harvard Apparatus Regenerative Technology, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Consumer Health Products [Member] | $982.00K | $885.00K | $704.00K | $743.00K | $679.00K | $418.00K | $430.00K | 100.0% | +44.6% |
| Regenerative Biotech [Member] | $0 | $0 | $0 | $0 | $0 | $0 | $0 | 0.0% | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Harvard Apparatus Regenerative Technology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.